Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | The prognostic value of self-reported fatigue on overall survival in patients with MDS

Fabio Efficace • 5 May 2023
MDS 2023
Myelodysplastic Syndromes

Fabio Efficace, PhD, Italian Group for Adult Hematologic Diseases (GIMEMA), Rome, Italy, comments on the prognostic value of self-reported fatigue on overall survival (OS) in patients with myelodysplastic syndromes (MDS), highlighting a new version of the IPSS which incorporates fatigue reports from high-risk patients with MDS (FA–IPSS[h]). This interview took place at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Disclosures

Consultancy/Advisory Board: Abbvie, Syros, Incyte, Janssen

More from Fabio Efficace

1:30
The prognostic value of patient-reported outcomes in MDS
Fabio Efficace • 5 May 2023
2:48
Developing effective methods to study QoL in clinical trials in MDS
Fabio Efficace • 5 May 2023
0:59
BMT CTN 1102: pre-transplantation QoL measures improve prognostication in HR-MDS
Fabio Efficace • 5 May 2023
0:45
Difference between quality of life & patient-reported outcomes
Fabio Efficace • 5 May 2023

Related Videos

2:22
Haplo-SCT for older patients with AML/HR-MDS: should age be a barrier to transplantation?
Raynier Devillier • 15 Apr 2024
2:31
Emerging treatment options for patients with ESA-refractory MDS: luspatercept & imetelstat
Eva Hellström-Lindberg • 11 Apr 2024
1:49
The unmet needs of patients with VEXAS syndrome
Maël Heiblig • 17 Apr 2024
1:25
The role of the bone marrow microenvironment in hematological malignancies
Manja Wobus • 17 Apr 2024
The content of VJHemOnc is intended for healthcare professionals